Genetic clues to fibrotic lung diseases: GENESIS Cohort
Official title: Genetic Etiologies of Subclassifiable ILD Study: the GENESIS Cohort study
Funded at University of Cincinnati · NIH-11453397 · Data updated 2026-11-12
A patient-centered study to understand inherited genetic causes of fibrotic interstitial lung diseases and lay the groundwork for future genetic-based therapies.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Cincinnati NIH-funded |
| Lab location | 1 site (Cincinnati, United States) |
| Project start | September 5, 2026 |
| Project end | July 31, 2031 |
| Funding year | 2026 |
| Award (this year) | $233,673 |
| NIH project number | 1U54HL188781-01 |
| Project ID | NIH-11453397 on NIH RePORTER |
Who could benefit from this research
✓Could help
Individuals with fibrotic interstitial lung diseases and related genetic questions who consent to genetic analyses and data sharing.
✕Less likely to help
Patients without genetic contributions or who do not consent to genetic analysis may see no direct benefit.
What this research studies
This project groups patients with fibrotic interstitial lung diseases to map inherited genetic variants that contribute to their condition. Scientists will use standardized genetic annotation and ClinGen resources to classify ILD genes with strong mutations, aiming to connect genetic signatures with disease patterns. Results could guide future trials and help develop targeted therapies that address the root genetic causes. Participation may involve genetic analysis of samples and sharing information that could inform personalized care. The work is led by the University of Cincinnati in collaboration with ClinGen and ILD experts.
Why it matters
Potential benefit: If successful, the study could enable more precise diagnoses and pave the way for genetics-guided therapies for fibrotic ILDs.
How similar studies have gone: Genetic-forward approaches have provided key insights in PF research and are becoming more actionable for targeted therapies.
Where this research is happening
-
University of Cincinnati
Cincinnati, United States Active
Researchers
- Principal investigator: Garcia, Christine Kim — University of Cincinnati
- Study coordinator: Garcia, Christine Kim
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.